Consistency of laboratory monitoring during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure

JAMA - Journal of the American Medical Association

Volumn 314, Issue 18, 2015, Pages 1973-1975

  Cooper, Lauren B ^a   Hammill, Bradley G ^a   Peterson, Eric D ^a   Pitt, Bertram ^b   Maciejewski, Matthew L ^c   Curtis, Lesley H ^a   Hernandez, Adrian F ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; MINERALOCORTICOID ANTAGONIST; POTASSIUM; SPIRONOLACTONE;

AGED; ANEMIA; ATRIAL FIBRILLATION; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CREATININE BLOOD LEVEL; DEMOGRAPHY; DRUG USE; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPOTHYROIDISM; LABORATORY TEST; LETTER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OSTEOPOROSIS; PATIENT MONITORING; POTASSIUM BLOOD LEVEL; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT OUTCOME; BLOOD; REGRESSION ANALYSIS;

AGED; FEMALE; HEART FAILURE; HUMANS; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; REGRESSION ANALYSIS;

EID: 84946761083     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.11904     Document Type: Letter

References (6)

1. Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J AmColl Cardiol. 2013;62(16):e147-e239.
2. Schneider KM, O'Donnell BE, Dean D. Prevalence of multiple chronic conditions in the United States' Medicare population. Health Qual Life Outcomes. 2009;7:82.
3. Pitt B, Zannad F, RemmeWJ, et al; Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709-717.
4. Zannad F, McMurray JJ, Krum H, et al; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21.
5. Hernandez AF,Mi X, Hammill BG, et al. Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. JAMA. 2012;308(20):2097-2107.
6. Wei L, Struthers AD, Fahey T,Watson AD, Macdonald TM. Spironolactone use and renal toxicity: population based longitudinal analysis. BMJ. 2010;340:c1768.